quinoxalines has been researched along with n,n'-dodecane-1,12-diyl-bis-3-picolinium dibromide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardo, MT; Crooks, PA; Dwoskin, LP; Joyce, BM; Neugebauer, NM; Pivavarchyk, M; Zhang, Z; Zheng, G | 1 |
| Cameron, P; Crooks, PA; Dwoskin, LP; Holt, JC; Jordan, PM; Kewin, K; Klapczynski, M; Lysakowski, A; McIntosh, JM | 1 |
2 other study(ies) available for quinoxalines and n,n'-dodecane-1,12-diyl-bis-3-picolinium dibromide
| Article | Year |
|---|---|
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzazepines; Brain; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drugs, Investigational; Male; Neurons; Nicotine; Nicotinic Antagonists; Picolines; Quaternary Ammonium Compounds; Quinoxalines; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Nicotinic; Reward; Smoking Cessation; Structure-Activity Relationship; Tobacco Use Disorder; Varenicline; Ventral Tegmental Area | 2009 |
Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents.
Topics: Animals; Azetidines; Benzazepines; Bungarotoxins; Cholinergic Agonists; Cholinergic Antagonists; Conotoxins; Female; Male; Motor Neurons; Picolines; Presynaptic Terminals; Protein Subunits; Pyridines; Quinoxalines; Receptors, Cholinergic; Turtles; Varenicline; Vestibular Nerve | 2015 |